Marrs Anna 4

4 · DOCUSIGN, INC. · Filed Jun 2, 2026

AI-generated summary of this filing

Updated Jun 2, 2026

DocuSign (DOCU) Director Anna Marrs Sells 365 Shares

What Happened

Anna Marrs, a director of DocuSign, reported multiple transactions: an open‑market sale of 365 shares on 2026-06-02 at $55.04 each for proceeds of $20,090; the exercise/conversion of 729 derivative shares on 2026-05-29 (reported at $0.00); and a grant/award of 4,384 restricted stock units (RSUs) reported 2026-06-01 (grant value reported as $0.00). The sale was effected under a pre-arranged Rule 10b5-1 trading plan.

Key Details

Transaction dates and prices:
- 2026-05-29: Exercise/conversion (derivative) of 729 shares @ $0.00 (reported as acquired and also reported as disposed as a derivative on same date).
- 2026-06-01: Grant of 4,384 RSUs @ $0.00.
- 2026-06-02: Open‑market sale of 365 shares @ $55.04 for $20,090 (F1: executed under a Rule 10b5-1 plan).
Shares owned after transaction: Not specified in the filing.
Notable footnotes:
- F1: Sale executed pursuant to a Rule 10b5-1 plan (pre‑arranged trading plan).
- F2–F5: RSUs represent contingent rights to one share each; the RSUs have specified vest commencement dates (May 29, 2025 and June 1, 2026) and generally vest in equal quarterly installments over one year with the fourth installment subject to earlier vesting conditions; RSUs do not expire.
Filing timeliness: Form 4 filed 2026-06-02 for transactions starting 2026-05-29. The filing does not indicate a late filing.

Context

The "exercise/conversion" entries relate to derivative instruments (here, RSUs per the footnotes) being converted into common shares. The paired acquisition and disposition lines for the 729 shares likely reflect conversion/settlement mechanics (reported as derivative activity) rather than a typical cash purchase.
The 4,384 RSUs are an award, not an immediate purchase; they vest over time per the footnotes, so they represent future potential shares rather than an immediate bullish cash investment.
The small open‑market sale (365 shares, ~$20k) under a 10b5‑1 plan is commonly a routine, pre‑arranged sale and should be interpreted differently than an opportunistic, unscheduled sale.

Form 4

Period: 2026-05-29

Director

Transactions

Exercise/Conversion
Common Stock
2026-05-29+729→ 12,980 total
Sale
Common Stock
[F1]
2026-06-02$55.04/sh−365$20,090→ 12,615 total
Exercise/Conversion
Restricted Stock Units
[F2][F3][F4]
2026-05-29−729→ 0 total
→ Common Stock (729 underlying)
Award
Restricted Stock Units
[F2][F5][F4]
2026-06-01+4,384→ 4,384 total
→ Common Stock (4,384 underlying)

Footnotes (5)

[F1]The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
[F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
[F3]The RSUs have a vest commencement date of May 29, 2025 and will vest in equal quarterly installments over one year, provided that the fourth quarterly installment shall vest in full on the earlier of (i) the date of the Company's next annual meeting of stockholders and (ii) the one year anniversary of the grant, in each case, subject to the Reporting Person being a service provider through each such date.
[F4]The RSUs do not expire; they either vest or are canceled prior to vesting date.
[F5]The RSUs have a vest commencement date of June 1, 2026 and will vest in equal quarterly installments over one year, provided that the fourth quarterly installment shall vest in full on the earlier of (i) the date of the Company's next annual meeting of stockholders and (ii) the one year anniversary of the grant, in each case, subject to the Reporting Person being a service provider through each such date.

Signature

/s/ Derrick Chapman, Attorney-in-fact|2026-06-02

1 file